Drug Search Results

Bambuterol

Alternative Names: bambuterol
Latest Update: 2024-01-30
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ADRB Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Qilu
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bambuterol

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
CTR20244653	P2	Recruiting	Unknown	None

Recent News Events

Date	Type	Title
01/30/2024	PubMed	Stability indicating eco-friendly quantitation of terbutaline and its pro-drug bambuterol using quantitative proton nuclear magnetic spectroscopy.
12/22/2023	PubMed	Rivastigmine-Bambuterol Hybrids as Selective Butyrylcholinesterase Inhibitors.
12/01/2023	PubMed	[Determination of 14 β-agonists in animal meat by ultra high performance liquid chromatography-tandem mass spectrometry].

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions